Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
09 12 2021
Historique:
received: 11 10 2021
revised: 30 11 2021
accepted: 06 12 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 1 1 2022
Statut: epublish

Résumé

In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP1) issued its first operational definition to diagnose sarcopenia. This was updated in 2019 with a revised sequence of muscle mass and muscle strength (EWGSOP2). The aim of the study was to investigate the impact of these different operational definitions on sarcopenia prevalence in a representative population-based sample. For each algorithm, the prevalence of sarcopenia-related categories was calculated and related to sociodemographic and lifestyle variables, anthropometric parameters, and laboratory biomarkers. The present analysis used data from the Salus in Apulia Study (Italy, 740 subjects, mean age 75.5 ± 5.9 years, 54% women). The application of the EWGSOP1 adapted algorithm resulted in 85% [95% confidence intervals (CI): 82-88%] non-sarcopenic subjects, 10% (95% CI: 8-12%) pre-sarcopenic subjects, and 5% (95% CI: 3-7%) sarcopenic/severe sarcopenic subjects. The sarcopenia-related categories were inversely related to weight and body mass index (BMI), particularly in overweight/obese subjects, and these categories showed favorable metabolic biomarkers. The EWGSOP2 algorithm yielded 73% (95% CI: 69-76%) non-sarcopenic subjects, 24% (95% CI: 21-27%) probably sarcopenic subjects, and 4% (95% CI: 2-5%) sarcopenic subjects. The present study identified BMI as a potential confounder of the prevalence estimates of sarcopenia-related categories in population-based settings with different EWGSOP operational definitions.

Sections du résumé

BACKGROUND
In 2010, the European Working Group on Sarcopenia in Older People (EWGSOP1) issued its first operational definition to diagnose sarcopenia. This was updated in 2019 with a revised sequence of muscle mass and muscle strength (EWGSOP2). The aim of the study was to investigate the impact of these different operational definitions on sarcopenia prevalence in a representative population-based sample.
METHODS
For each algorithm, the prevalence of sarcopenia-related categories was calculated and related to sociodemographic and lifestyle variables, anthropometric parameters, and laboratory biomarkers. The present analysis used data from the Salus in Apulia Study (Italy, 740 subjects, mean age 75.5 ± 5.9 years, 54% women).
RESULTS
The application of the EWGSOP1 adapted algorithm resulted in 85% [95% confidence intervals (CI): 82-88%] non-sarcopenic subjects, 10% (95% CI: 8-12%) pre-sarcopenic subjects, and 5% (95% CI: 3-7%) sarcopenic/severe sarcopenic subjects. The sarcopenia-related categories were inversely related to weight and body mass index (BMI), particularly in overweight/obese subjects, and these categories showed favorable metabolic biomarkers. The EWGSOP2 algorithm yielded 73% (95% CI: 69-76%) non-sarcopenic subjects, 24% (95% CI: 21-27%) probably sarcopenic subjects, and 4% (95% CI: 2-5%) sarcopenic subjects.
CONCLUSIONS
The present study identified BMI as a potential confounder of the prevalence estimates of sarcopenia-related categories in population-based settings with different EWGSOP operational definitions.

Identifiants

pubmed: 34948590
pii: ijerph182412979
doi: 10.3390/ijerph182412979
pmc: PMC8700814
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nutrients. 2020 Feb 07;12(2):
pubmed: 32046004
J Gerontol A Biol Sci Med Sci. 2005 Jun;60(6):760-7
pubmed: 15983180
Curr Opin Clin Nutr Metab Care. 2019 Jan;22(1):13-19
pubmed: 30461451
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58
pubmed: 24737557
Age Ageing. 2020 Feb 27;49(2):300-304
pubmed: 31728486
Front Physiol. 2017 Feb 15;8:87
pubmed: 28261109
BMC Geriatr. 2013 Jul 16;13:74
pubmed: 23865675
BMC Geriatr. 2020 Nov 10;20(1):461
pubmed: 33172391
Exp Gerontol. 2020 Feb;130:110798
pubmed: 31816424
Aging Clin Exp Res. 2021 Oct;33(10):2879-2882
pubmed: 33501623
Eur J Clin Nutr. 2020 Jul;74(7):1104-1108
pubmed: 31767990
J Nutr Health Aging. 2020;24(7):783-790
pubmed: 32744576
Front Aging Neurosci. 2014 Jul 28;6:192
pubmed: 25120482
Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Aug 6;51(8):746-750
pubmed: 28763926
Arch Gerontol Geriatr. 2020 Jul - Aug;89:104081
pubmed: 32485520
Eur Geriatr Med. 2020 Apr;11(2):239-246
pubmed: 32297186
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):512-514
pubmed: 27891296
Clin Nutr. 2015 Aug;34(4):667-73
pubmed: 25103151
Sci Rep. 2016 Jan 20;6:19457
pubmed: 26785759
J Obes Metab Syndr. 2018 Sep 30;27(3):175-185
pubmed: 31089560
J Appl Physiol (1985). 2000 Jul;89(1):81-8
pubmed: 10904038
Age Ageing. 2019 Jul 1;48(4):601
pubmed: 31081853
J Am Geriatr Soc. 2009 Feb;57(2):251-9
pubmed: 19207142
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1575-1581
pubmed: 28329345
PLoS One. 2014 Nov 03;9(11):e111810
pubmed: 25365291
Curr Opin Clin Nutr Metab Care. 2018 Sep;21(5):366-374
pubmed: 29957677
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
Age Ageing. 2019 Nov 1;48(6):910-916
pubmed: 31329815
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Obes Facts. 2018;11(4):294-305
pubmed: 30016792
Clinics (Sao Paulo). 2019 Apr 08;74:e477
pubmed: 30994709
Clin Nutr. 2016 Dec;35(6):1557-1563
pubmed: 26922142
J Gerontol A Biol Sci Med Sci. 2020 Jun 18;75(7):1324-1330
pubmed: 32157272
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Age Ageing. 2019 Sep 1;48(5):719-724
pubmed: 31112221
J Diabetes Metab Disord. 2017 May 16;16:21
pubmed: 28523252
Geriatr Gerontol Int. 2019 Jul;19(7):593-597
pubmed: 31006968
J Nutr Health Aging. 2019;23(9):771-787
pubmed: 31641726
Geriatr Gerontol Int. 2019 Mar;19(3):272
pubmed: 30821065
Korean J Intern Med. 2016 Jul;31(4):643-50
pubmed: 27334763
J Appl Physiol (1985). 2000 Aug;89(2):465-71
pubmed: 10926627
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Am J Prev Med. 2006 Sep;31(3):217-24
pubmed: 16905032
Aging Male. 2020 Dec;23(5):382-387
pubmed: 30269625

Auteurs

Luisa Lampignano (L)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Ilaria Bortone (I)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Fabio Castellana (F)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Rossella Donghia (R)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Vito Guerra (V)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Roberta Zupo (R)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Giovanni De Pergola (G)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.
Department of Biomedical Science and Human Oncology, School of Medicine, University of Bari Aldo Moro, 70100 Bari, Italy.

Marta Di Masi (M)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Gianluigi Giannelli (G)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Madia Lozupone (M)

Center for Neurodegenerative Diseases and the Aging Brain, Department of Basic Medicine, Neuroscience, and Sense Organs, University of Bari Aldo Moro, 70100 Bari, Italy.

Francesco Panza (F)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Heiner Boeing (H)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.
Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, 14558 Nuthetal, Germany.

Rodolfo Sardone (R)

National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Castellana Grotte, 70013 Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH